[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Florida, no childhood vaccinations", "description": "Free PDFs of my two text books, direct link for downloads, http://159.69.48.3/\n\nPhysiology book in hard copy\n\nhttps://www.ebay.co.uk/itm/154770452796?mkevt=1&mkcid=16&mkrid=710-127635-2958-0\n\n0:00 start \n1:25 it is essential that health care practitioners review all data\n1:45 to evaluate risk and benefits, unique to each patient \n2:11 when determining what health care services to provide, \n2:37 including the administration of covid-19 vaccines \n2:53 these decisions should be made on an individual basis (Topic on providing unique care according to individual needs)\n3:15 risk of administering a covid-19 vaccine to healthy children may outweigh the benefits\n3:25 Healthy children aged 5 to 17 may not benefit from receiving the currently available COVID-19 vaccine\n3:39 children with underlying conditions are the best candidates for the COVID-19 vaccine\nLooking at the evidence \n4:00 risk that may outweigh benefits among healthy children with no underlying conditions\n4:12 limited risk of severe illness due to COVID-19\n5:00 Keynotes: Paper was used in Delta times, you ideally want something more current. The following are points true according to delta times \n5:34 Although Covid-19 is generally milder in children than adults \n5:39 severe illness and long-term complications, including multisystem inflammatory syndrome in children (MIS-C), can occur after primary infection \n6:11 Evaluation of the BNT162b2 Covid-19 Vaccine in children 5 to 11 years of AGE (NEJM)\n8:42 argument: There is high prevalence of existing immunity among children \n11:18 The absence of data informing benefit of COVID-19 vaccination among children with existing immunity (agrees with the Florida study)\n12:19 in clinical trials, higher than anticipated serious adverse events occurred among those receiving the covid-19 vaccine. (reference unclear to this claim) \n14:43 Reduced vaccine efficacy in with omicron, Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant \n16:27 the effectiveness against cases of BNT162b2 declined rapidly for children, particularly those 5-11\n16:48 However, vaccination of children 5-11 years was protective against severe disease and is recommended\n17:53 Risk of myocarditis due to the COVID-19 vaccine, Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 (JAMA, 2022) \n20:19 Vaccine efficacy wanes rapidly (the percentage drop shown for children and adolescents) \n21:40 Recommended for children with underlying health conditions or comorbidities \n22:08 in general, healthy children with no significant underlying health conditions under 16 years old are at little to no risk of severe illness complications from covid-19, For adolescents, the risk of myocarditis du\r\n\nFlorida\nhttps://floridahealthcovid19.gov/wp-content/uploads/2022/03/g2-jtr_QWBT4hJpqr.pdf?utm_source=floridahealth.gov&utm_medium=referral&utm_campaign=covid-19&utm_term=fdoh+issues+new+guidance+regarding+covid-19+vaccination+recommendations+for+children&utm_content=press_release&url_trace_7f2r5y6=hcgyu2mu94atfcyvdgsa\n\nChildren with underlying conditions are the best candidates for the COVID-19 vaccine. \n\nEvaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (NEJM)\n\n(Delta time data)\n\nhttps://www.nejm.org/doi/full/10.1056/nejmoa2116298\n\nEvaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (NEJM)\n\nhttps://www.nejm.org/doi/full/10.1056/nejmoa2116298\n\nN = 2,268, (phase 2 clinical trial)\n\nhttps://covid19serohub.nih.gov\n\nNIH covid SeroHub\n\nhttps://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event\n\nReduced vaccine efficacy in with omicron\n\nEffectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant\n\nhttps://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1\n\nNew York State Department of Health\n\nDecember 13, 2021 to January 30, 2022\n\nAged 12 \u2013 17, n = 852,384 fully-vaccinated\n\nAged, 5 \u2013 11 years, n = 365,502 fully-vaccinated\n\nRisk of myocarditis due to the COVID-19 vaccine\n \nMyocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021(JAMA, 2022)\n\nhttps://jamanetwork.com/journals/jama/fullarticle/2788346\n\n(70.7 per million doses of the BNT162b2 vaccine)\n\nin adolescent males aged 16 to 17 years\n\n(105.9 per million doses of the BNT162b2 vaccine)\n\nin young men aged 18 to 24 years\n\n(52.4 per million doses of BNT162b2)\n \n(56.3 per million doses of \nmRNA-1273 )\n\nhttps://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1", "link": "https://www.youtube.com/watch?v=TWPXRRVsAGk", "date_published": "2022-03-10 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "The Pfizer documents", "description": "Public Health and Medical Professionals for Transparency, Pfizer / FDA FOI\n\nhttps://phmpt.org\n\nRequest, Freedom of Information Act (FOIA) \n\nhttps://phmpt.org/wp-content/uploads/2021/10/IR0546-FDA-Pfizer-Approval-FINAL.pdf\n\nAgainst FDA\n\nhttps://phmpt.org/wp-content/uploads/2021/10/001-Complaint-101021.pdf\n\nThe court order\n\nhttps://phmpt.org/wp-content/uploads/2022/02/056-ORDER-GRANTING-IN-PART-THE-MOTION-TO-MODIFY-THE-PRODUCTION-SCHEDULE-AND-ADDOPTS-THE-JOINT-STATUS-REPORT-MODIFIED-AGREED-PRODUCTION-SCHEDULE.pdf\n\nList of downloadable documents\n\nhttps://phmpt.org/pfizers-documents/\n\n5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021 \n\nhttps://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf\n\nAdverse event reports \n\n01 December 2020 through 28 February 2021\n \nCumulatively, through 28 February 2021, \n\na total of 42,086 case reports (25,379 medically confirmed and 16,707 non-medically confirmed) \n\ncontaining 158,893 events. \n\nMost cases (34,762) were received from United States (13,739), \n\nUnited Kingdom (13,404) \n\nItaly (2,578), \n\nGermany (1,913), \n\nFrance (1,506), \n\nPortugal (866) and \n\nSpain (756)\n\nthe remaining 7,324 were distributed among 56 other countries. \n\nFatal, 1,223\n\nSince Dec. 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA \n\nhttps://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine\n\n(Approval, 21st August 2021)\n\nActing FDA Commissioner Janet Woodcock, M.D.\n\nWhile millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. \n\nToday\u2019s milestone puts us one step closer to altering the course of this pandemic in the U.S.\n\nSystem Organ Classes (SOCs)\n\nthat contained the greatest number (\u22652%) of events, in the overall dataset, \n\nwere General disorders and administration site conditions (51,335 AEs), \n\nNervous system disorders (25,957), \n\nMusculoskeletal and connective tissue disorders (17,283), \n\nGastrointestinal disorders (14,096), \n\nSkin and subcutaneous tissue disorders (8,476), \n\nRespiratory, thoracic and mediastinal disorders (8,848), \n\nInfections and infestations (4,610), \n\nInjury, poisoning and procedural complications (5,590), and Investigations (3,693). \n\nCardiovascular AESIs \n\nNumber of cases: 1403 (3.3% of the total PM dataset), \n\nof which 241 are medically confirmed and 1162 are non-medically confirmed; \n\n5. SUMMARY AND CONCLUSION \nReview of the available data for this cumulative PM experience, confirms a favorable benefit: risk balance for BNT162b2. \n\nPeter Marks, M.D., Ph.D., director of FDA\u2019s Center for Biologics Evaluation and Research\n\n\u201cOur scientific and medical experts conducted an incredibly thorough and thoughtful evaluation of this vaccine. \n\nWe evaluated scientific data and information included in hundreds of thousands of pages, conducted our own analyses of Comirnaty\u2019s safety and effectiveness, \n\nand performed a detailed assessment of the manufacturing processes, including inspections of the manufacturing facilities,\u201d\n\n\u201c\u2026.. the public is counting on safe and effective vaccines. The public and medical community can be confident that although we approved this vaccine expeditiously, it was fully in keeping with our existing high standards for vaccines in the U.S.\"\n\nhttps://childrenshealthdefense.org/defender/fda-releases-pfizer-vaccine-documents/?itm_term=home\n\nAustria\n\nhttps://www.nytimes.com/live/2022/03/09/world/covid-19-mandates-cases-vaccine\n\nKaroline Edtstadler\n\nthe law, passed in January, in force since early February, \n\nnot proportionate, relatively mild symptoms experienced by most people who contract Omicron", "link": "https://www.youtube.com/watch?v=7YOD9drZasM", "date_published": "2022-03-09 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]